LATANOPROST

LATANOPROST

Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5- heptenoate; Xalatan; Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl- 18,19,20- trinor-prost-5-en-1-oate;

LATANOPROST

PRODUCT IDENTIFICATION
CAS RN	130209-82-4
EINECS RN
FORMULA	C₂₆H₄₀O₅
MOLE WEIGHT	432.59
CLASSIFICATION	Prostaglandin analogue / Antiglaucoma

PHYSICAL AND CHEMICAL PROPERTIES
PHYSICAL STATE	clear to pale yellow viscous oil
MELTING POINT
BOILING POINT
DENSITY
SOLUBILITY IN WATER	(Freely soluble in DMSO, soluble in methanol)
pH
VAPOR DENSITY
REFRACTIVE INDEX
FLASH POINT

STABILITY AND REACTIVITY
STABILITY	Stable under normal conditions.
INCOMPATIBLE MATERIALS	Strong acids, Strong bases
DECOMPOSITION PRODUCTS	Carbon monoxide, Carbon dioxide
POLYMERIZATION	Has not been reported
NFPA RATINGS	Health Hazard: 4, Fire: 0, Reactivity Hazard: 0

SAFETY
HAZARD NOTES	Highly toxic by ingestion
EYE	May cause eye irritation.
SKIN	May be harmful if absorbed through skin. May cause skin irritation.
INGESTION	May be harmful if swallowed.
INHALATION	May be fatal if swallowed.
CHRONIC

TRANSPORT & REGULATORY INFORMATION
UN NO.
HAZARD CLASS
PACKING GROUP
HAZARD SYMBOL
RISK PHRASES
SAFETY PHRASES	22-36/37-61

EXTERNAL LINKS & GENERAL INFORMATION

Latanoprost is a prescription medication used for reducing eye pressure. Specifically, it is used to lower eye pressure in people with open angle glaucoma or ocular hypertension to help prevent damage to the optic nerve. Latanoprost comes in the form of an eye drop that is generally used once daily. Common side effects include changes in eye color, blurred vision, and eyelash and eyelid changes. http://eyes.emedtv.com/latanoprost/latanoprost.html

The fundamental rationale for treating glaucoma is that abnormal IOP plays a major role in glaucomatous optic neuropathy. Although high IOP is certainly not the only factor contributing to ON damage, it is one of the few risk factors that can be clinically modified. Medically lowering IOP in patients with OH may reduce the incidence of glaucoma.134 In at least two-thirds of patients with high-tension glaucoma, marked lowering of the IOP stops progression of the disease. Even in NTG patients, the level of the IOP is a risk factor related to the degree of glaucomatous damage. (http://www.aoa.org/)

Topical beta blockers are the standard first-line agents, most commonly timolol (Timoptic). Newer beta blockers include betaxolol (Betoptic), levobunolol (Betagan), carteolol (Ocupress), and metipranolol (OptiPranolol). Timolol has been used for years, and these agents are well tolerated.
Topical prostaglandins are alternatives if beta blockers fail. They include latanoprost (Xalatan) and unoprostone (Rescula). Of the standard agents used for glaucoma, these agents have the greatest effect on lowering IOPs. They also have fewer widespread effects than the beta blockers.
Topical carbonic anhydrase inhibitors (CAIs) are less effective than standard beta blockers or prostaglandins but have fewer widespread effects than the beta blockers. They may be helpful in certain cases. Topical forms are dorzolamide (Trusopt) and brinzolamide (Azopt). (Oral CAIs are available and more effective, but they have severe side effects and are rarely used for the long term.)
Alpha2-adrenergics, also called selective alpha adrenergics, are effective but may not be as well tolerated as timolol. They include brimonidine (Alphagan, Allergan).
Miotics, which include pilocarpine and others, were the standard agents before the introduction of topical beta blockers. They have now been largely replaced by timolol and others, although they are sometimes used in combinations.
Beta blockers and newer agents (prostaglandins, topical CAIs, and selective alpha adrenergics) are now preferred over the older agents, which include miotics, oral CAIs, and nonselective alpha adrenergics. (http://adam.about.com/)

Pharmacological Actions

Antiglaucoma agent
Antihypertensive Agent
Cardiovascular Agent
Prostanoid Receptor Agonist

Antiglaucoma
Product	CAS RN.
Acetazolamide	59-66-5
Alprenoxime hydrochloride	121009-30-1
Apraclonidine	66711-21-5
Betaxolol	63659-18-7
Bimatoprost	155206-00-1
Brimonidine	59803-98-4
Brinzolamide	138890-62-7
Carbachol	51-83-2
Carteolol	51781-06-7
Colforsin	66575-29-9
Dapiprazole	72822-12-9
Dichlorphenamide	120-97-8
Dipivefrin	52365-63-6
Dorzolamide	120279-96-1
Latanoprost	130209-82-4
Levobunolol	47141-42-4
Methazolamide	554-57-4
Metipranolol	22664-55-7
Naboctate hydrochloride	73747-21-4
Pilocarpine	92-13-7
Pirnabine	19825-63-9
Timolol	26839-75-8
Travoprost	157283-68-6

SALES SPECIFICATION
APPEARANCE	white to slightly yellowish powder
IDENTIFICATION	pass Test A (HPLC),B (IR)
ASSAY	98.0% ~ 102.0%
WATER	0.5% max
SOLVENT RESIDUE	Ethanol 1.0% max n-Hexane: 0.05% max
ISOMERS	15(S)-cis isomer: 0.1% max 15(S)-trans isomer : 0.1% max 15(R)-trans isomer: 0.1% max
TOTAL IMPURITY	1.0% max
OPTICAL ROTATION	+32° ~ +38°

PACKING

PRICE INFORMATION